Results 81 to 90 of about 100,944 (279)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Herpes Zoster After Tocilizumab Therapy in COVID-19 Survivor: A Case Report

open access: yesActa Medica Indonesiana, 2022
The COVID-19 pandemic has become a concern for the world community. However, despite abundant attempts taking place, there is currently no definitive therapy for COVID-19 yet.
Suwenny Suwenny, Sahat Halim
doaj   +2 more sources

Treatment of adult-onset Still's disease: a review [PDF]

open access: yes, 2014
Adult-onset Still's disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. The former classification, based on the disease course, seems to be quite dated.
Gerfaud-Valentin, M.   +3 more
core   +3 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study

open access: yesRheumatology and Therapy, 2018
Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).
Boulos Haraoui   +5 more
doaj   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

open access: yesAdvanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak   +9 more
wiley   +1 more source

Rituximab induced pulmonary edema managed with extracorporeal life support [PDF]

open access: yes, 2018
Though rare, rituximab has been reported to induce severe pulmonary edema. We describe the first report of ECLS utilization for this indication. A 31-year-old female with severe thrombotic thrombocytopenic purpura developed florid pulmonary edema after ...
Aguilar, Patrick   +6 more
core   +3 more sources

A Keratinocyte‐Mast Cell NF‐κB2/CXCL2/IL‐6 Amplification Loop Enhances Cutaneous Antifungal Defense Against C. albicans

open access: yesAdvanced Science, EarlyView.
ABSTRACT Mast cells (MCs), key innate immune sentinels at the host–environment interface, serve as primary responders to invading pathogens. However, their specific contribution to host defense against cutaneous Candida albicans (C. albicans) infection and their synergy with other immune and non‐immune cells remain poorly understood. Here, we show that
Yan Yuan   +12 more
wiley   +1 more source

ANXA2‐mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy